Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Limited Asian Fallout From Pfizer-Allergan Merger?

This article was originally published in Scrip

Executive Summary

As far as Asian and emerging pharma markets go, it is clear that Pfizer Inc. will be the dominant partner in the planned $160bn merger with Allergan PLC. The US firm has a broad reach in these areas that Allergan will be looking to tap into, and major restructuring in big regional markets such as China and Japan looks unlikely.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts